News | June 24, 2013

Emory Proton Therapy Center Breaks Ground in Atlanta

Emory Proton Therapy Center Breaks Ground Atlanta

June 24, 2013 — A new first for Georgia was celebrated Thursday, May 2, as Emory Healthcare and the Winship Cancer Institute broke ground on the new Emory Proton Therapy Center. Brasfield & Gorrie, the general contractor on the more than $200 million dollar oncology center, was joined in the celebration by developer Advanced Particle Therapy and elected officials, including Atlanta Mayor Kasim Reed.

In his remarks, Mayor Reed addressed the center’s impact, not only on the lives of patients but also on the city’s economic and research development.

Located in downtown Atlanta at the corner of Peachtree Street and North Avenue, the 107,000 square foot center will accommodate approximately 2,200 cancer patients each year. The facility will open its doors to patients in 2016 after an 18-month commissioning period for the Varian Medical Systems equipment.

The new proton treatment facility will incorporate several unique features, including the 16-foot-thickspecialized shielding walls necessary to house pencil beam scanning equipment. To date, only one proton therapy center in the nation offers pencil beam scanning capabilities and in only one room. The Emory Proton Therapy Center will feature this advanced capability in all five of its treatment rooms.

Under the direction of developer Advanced Particle Therapy, Brasfield & Gorrie is working with Signet Development, Emory Healthcare, VOA Associates and Perkins+Will.

“This facility represents a wonderful opportunity to fulfill a health care need for the people of Georgia and surrounding states. We look forward to a successful building process and turning over a treatment center that will improve the lives of many patients,” said Trey Sanders, regional president of Brasfield & Gorrie.

For more information: www.brasfieldgorrie.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...